---
title: "BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291003611.md"
description: "BriaCell subsidiary BriaPro reported $1.32M in total assets and $299,950 in cash as of April 30, 2026. The company acquired an exclusive sCD80 license for $846,532 via share issuance. Despite a nine-month net loss of $712,236 and negative working capital, BriaCell provided financial support including a $300,000 advance and a $3M credit facility to fund sCD80 R&D."
datetime: "2026-06-26T20:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291003611.md)
  - [en](https://longbridge.com/en/news/291003611.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291003611.md)
generator: "portal-rs"
---

# BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisition

**BriaCell Therapeutics subsidiary BriaPro reported interim results showing $1.32 million in total assets and completed an $846,532 sCD80 license acquisition funded by share issuance.**

**Key Highlights:**

-   Unaudited interim statements for period ended April 30, 2026 filed; total assets $1,321,744 and cash $299,950.
-   Acquired exclusive sCD80 license on March 31, 2026 by issuing 23,972,589 shares, recorded as $846,532 intangible asset.
-   Nine-month net loss $712,236; accumulated deficit $1,892,661 and negative working capital $1,937,495 as of April 30, 2026.
-   BriaCell provided $300,000 cash advance and a credit facility up to $3,000,000 (5% interest) to support sCD80 R&D.
-   Warrant liability revaluation produced $110,088 gain for nine months, reducing warrant liability to $71,855.

Original SEC Filing: BriaCell Therapeutics Corp. \[ BCTX \] - 8-K - Jun. 26, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BCTXZ.US](https://longbridge.com/en/quote/BCTXZ.US.md)
- [BCTX.US](https://longbridge.com/en/quote/BCTX.US.md)
- [BCTXW.US](https://longbridge.com/en/quote/BCTXW.US.md)
- [BCTXL.US](https://longbridge.com/en/quote/BCTXL.US.md)

## Related News & Research

- [BriaCell says Bria-MEL+ melanoma vaccine candidate hits genetic engineering milestone](https://longbridge.com/en/news/296780600.md)
- [BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ | BCTX Stock News](https://longbridge.com/en/news/296784224.md)
- [$1000 Invested In Watts Water Technologies 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296960055.md)
- [02:10 ETKeymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt](https://longbridge.com/en/news/296866579.md)
- [02:03 ETConfigit est nommé Sample Vendor dans le rapport Hype Cycle™ for Revenue and Sales Technology, 2026 de Gartner®](https://longbridge.com/en/news/296865895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**